Julian Harrison
Stock Analyst at BTIG
(4.96)
# 109
Out of 4,339 analysts
484
Total ratings
53.6%
Success rate
44.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reiterated: Buy | $38 | $15.46 | +145.80% | 21 | May 19, 2026 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.4002 | - | 19 | May 18, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $151 | $59.06 | +155.67% | 11 | May 13, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $58 | $16.02 | +262.05% | 10 | May 13, 2026 | |
| CNTB Connect Biopharma Holdings | Maintained: Buy | $10 | $2.40 | +316.67% | 5 | May 12, 2026 | |
| LQDA Liquidia | Maintained: Buy | $50 → $59 | $60.10 | -1.82% | 43 | May 11, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Buy | $30 | $18.23 | +64.56% | 31 | May 11, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $137 | $82.81 | +65.44% | 25 | May 11, 2026 | |
| TVRD Tvardi Therapeutics | Maintained: Buy | $15 | $3.42 | +338.60% | 6 | May 8, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $178 | $65.56 | +171.51% | 17 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $42 | $22.68 | +85.19% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $16.41 | +27.97% | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $73.65 | +33.06% | 20 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 → $19 | $11.39 | +66.81% | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.04 | +284.62% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $21.71 | +79.64% | 16 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $46 | $26.35 | +74.57% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $3.30 | +51.52% | 15 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.3337 | +199.67% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $578.43 | - | 19 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $150 | $126.41 | +18.66% | 12 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $6.25 | +172.00% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $44 | $6.45 | +582.17% | 8 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $17.00 | +258.82% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $82 | $99.98 | -17.98% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6795 | - | 7 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $0.9405 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $164 | $50.26 | n/a | 8 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.23 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $57.65 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $4.51 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $7.61 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $0.728 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.0001 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $30.80 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $1.78 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.25 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $4.77 | n/a | 1 | Dec 9, 2020 |
Cullinan Therapeutics
May 19, 2026
Reiterated: Buy
Price Target: $38
Current: $15.46
Upside: +145.80%
Outlook Therapeutics
May 18, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.4002
Upside: -
Oruka Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $151
Current: $59.06
Upside: +155.67%
Avalo Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $58
Current: $16.02
Upside: +262.05%
Connect Biopharma Holdings
May 12, 2026
Maintained: Buy
Price Target: $10
Current: $2.40
Upside: +316.67%
Liquidia
May 11, 2026
Maintained: Buy
Price Target: $50 → $59
Current: $60.10
Upside: -1.82%
MoonLake Immunotherapeutics
May 11, 2026
Reiterated: Buy
Price Target: $30
Current: $18.23
Upside: +64.56%
Apogee Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $137
Current: $82.81
Upside: +65.44%
Tvardi Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $15
Current: $3.42
Upside: +338.60%
Nektar Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $178
Current: $65.56
Upside: +171.51%
May 7, 2026
Maintained: Buy
Price Target: $35 → $42
Current: $22.68
Upside: +85.19%
May 7, 2026
Maintained: Buy
Price Target: $21
Current: $16.41
Upside: +27.97%
May 6, 2026
Reiterated: Buy
Price Target: $98
Current: $73.65
Upside: +33.06%
May 6, 2026
Rated: Buy
Price Target: $8 → $19
Current: $11.39
Upside: +66.81%
Apr 6, 2026
Maintained: Buy
Price Target: $4
Current: $1.04
Upside: +284.62%
Apr 2, 2026
Maintained: Buy
Price Target: $39
Current: $21.71
Upside: +79.64%
Mar 25, 2026
Maintained: Buy
Price Target: $46
Current: $26.35
Upside: +74.57%
Mar 24, 2026
Maintained: Buy
Price Target: $5
Current: $3.30
Upside: +51.52%
Mar 19, 2026
Maintained: Buy
Price Target: $1
Current: $0.3337
Upside: +199.67%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $578.43
Upside: -
Feb 23, 2026
Maintained: Buy
Price Target: $150
Current: $126.41
Upside: +18.66%
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $6.25
Upside: +172.00%
Nov 14, 2025
Maintained: Buy
Price Target: $42 → $44
Current: $6.45
Upside: +582.17%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $17.00
Upside: +258.82%
Nov 3, 2025
Maintained: Buy
Price Target: $82
Current: $99.98
Upside: -17.98%
Jul 31, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.6795
Upside: -
Mar 31, 2025
Maintained: Buy
Price Target: $14
Current: $0.9405
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $164
Current: $50.26
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $11.23
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $57.65
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $4.51
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $24
Current: $7.61
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $0.728
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.0001
Upside: n/a
Apr 28, 2021
Maintained: Buy
Price Target: $12
Current: $30.80
Upside: n/a
Apr 27, 2021
Maintained: Buy
Price Target: $29
Current: $1.78
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.25
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $4.77
Upside: n/a